Hydergine is a combination of the mesylated forms of dihydroergocornine, dihydroergocristine, dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine. In animal models and healthy elderly volunteers the compound improves indices of cognitive function such as memory and learning. The mechanism(s) behind such action remains under investigation. Nonetheless, it has been proposed that co-dergocrine mesylate has a dual effect on central monoaminergic neurotransmitter systems, compensating for both hyperactivity and deficits of the adrenergic, serotoninergic and dopaminergic systems. The compound also appears to have a normalising effect on the power of electroencephalogram frequencies, and may improve cerebral metabolism. Results from controlled studies of elderly patients with age-related cognitive decline have established that co-dergocrine mesylate is well tolerated and, in some studies, had statistically significant positive effects on symptoms of cognitive dysfunction.

Hydergine was originally developed as an anti-hypertensive medication, but it was soon found that it really wasn't very effective in reducing elevated blood pressure. However, a number of people who used it did report improvements in memory, mood and overall sense of well being. At first, it was believed that these effects were due to increased cerebral blood flow. Later, however, it was determined that Hydergine actually acted to improve brain cell metabolism in a number of ways.

Hydergine increases stores of the universal energy molecule, adenosine triphosphate (ATP), stabilises the intracellular messenger molecule cyclic adenosine monophosphate (cAMP) content of nerve cells, improves utilization of glucose in the brain, and enhances cerebral microcirculation.

The FDA approves Hydergine for persons ?over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity,? (i.e. cognitive and interpersonal skills, mood, self-care, apparent motivation-Physician's Desk Reference 1995). It should be noted that the modest but significant changes referred to above were all in the positive direction. It should also be noted that these improvements all took place using the measly 3mg dose that is approved and most commonly used in the USA.

The above combined clinical and laboratory data support the recommendation of many anti-aging physicians that Hydergine should continue to be incorporated in an anti-aging/ smart drug regimen. Although the FDA approved recommended dosage in the US remains 3mg per day- and many people do well on 2-3mg per day, most antiaging scientists believe that most life extensionists would benefit by somewhat higher doses.

Before taking any prescription medicine, it is important that you consult your doctor!